We assessed the management and outcomes among hospitalized patients with coronary artery disease (CAD), stroke, peripheral artery disease (PAD), or with multiple (≥2) cardiovascular (CV) risk factors (multiple risk factors [MRFs]). We retrospectively studied 3732 hospitalized patients of either CV disease or ≥2 risk factors for atherothrombosis from October 2004 to January 2005. Outcomes included CV death, myocardial infarction (MI), stroke, and hospitalization for atherothrombotic events. About one-third had disease involving ≥1 vascular bed. Medication was more intense in patients with CAD than in others. The lowest use of statins and antiplatelet treatment was in the PAD-only group. Patients with PAD experienced a higher CV mortality (5.1%) than the patients with CAD (3.73%) or stroke (4.1%), P < .001. Cardiovascular death ranged from 1.2% for patients with MRFs, 2.8% for patients with 1-bed disease, 4.7% for patients with 2-bed disease to 6.4% for patients with 3-bed disease (P for trend <.001). For hospitalized patients with established atherosclerotic arterial disease, a substantial increase in CV event rates occurs with increasing numbers of affected arterial beds. Patients with PAD were at an especially high risk.
MurrayCJLopezAD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349(9063):1436–1442.
2.
WangWHuSSKongLZ. Summary of report on cardiovascular diseases in China, 2012. Biomed Environ Sci. 2014;27(7):552–558.
3.
LiuL. Cardiovascular diseases in China. Biochem Cell Biol. 2007;85(2):157–163.
4.
NiuSZhaoDZhuJ. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. Am Heart J. 2009;157(4):709–715. e701.
5.
WeiJWHeeleyELWangJG. Comparison of recovery patterns and prognostic indicators for ischemic and hemorrhagic stroke in China: the ChinaQUEST (QUality Evaluation of Stroke Care and Treatment) Registry study. Stroke. 2010;41(9):1877–1883.
6.
Bridging the Gap on Coronary Heart Disease Secondary Prevention in China. Analysis of current treatment practice and outcomes for in-patients with ST-segment elevation acute coronary syndrome in 31 provinces of China. Beijing Da Xue Xue Bao. 2011;43(3):440–445.
7.
LiXLiJNguyenT. Effect of statins and calcium channel blockers on all-cause mortality and cardiovascular and cerebrovascular disease mortality in 958 Chinese hospitalized patients with peripheral arterial disease after 13 months of follow-up. J Health Sci. 2007;53(2):226–233.
8.
YangJGLiJLuCHasimuBYangYHuD. Chronic kidney disease, all-cause mortality and cardiovascular mortality among Chinese patients with established cardiovascular disease. J Atheroscler Thromb. 2010;17(4):395–401.
9.
WalkerAERobinsMWeinfeldFD. The national survey of stroke. Clinical findings. Stroke. 1981;12(2 pt 2 suppl 1):I13–I144.
10.
ZhaoLZhouBWuYLiYYangJ. A prospective study on body mass index and mortality. Zhonghua Liu Xing Bing Xue Za Zhi. 2002;23(1):24–27.
11.
CacoubPPAbolaMTBaumgartnerI. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204(2):e86–e92.
12.
JamesPAOparilSCarterBL. 2014evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
13.
JacobsonTAItoMKMakiKC. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8(5):473–488.
14.
RoalfeAKHolderRLWilsonS. Standardisation of rates using logistic regression: a comparison with the direct method. BMC Health Serv Res. 2008;8:275.
15.
BhattDLStegPGOhmanEM. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189.
16.
FowkesFGLowLPTutaSKozakJ. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27(15):1861–1867.
17.
StegPGBhattDLWilsonPW. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–1206.
18.
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339.
19.
YusufSSleightPPogueJBoschJDaviesRDagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153.
20.
WangYXuYLiJ. Characteristics of prevalence in peripheral arterial disease and correlative risk factors and comorbidities among female natural population in China. VASA. 2010;39(4):305–311.
21.
GaxiolaEEng-CecenaLOrtiz-GalvanF. Assessment of atherothrombosis and its treatment in Mexico: first-year data of the REACH Registry. Clin Cardiol. 2010;33(7):445–451.
22.
MoyerVAForceUSPST. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):342–348.
23.
BhattDL. Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. J Invasive Cardiol. 2003;15(suppl B):3B–9B; discussion9B–10B.
24.
HasimuBLiJYuJ. Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients. Circ J. 2007;71(1):95–99.
25.
LiXGaoYLiJ. Underuse of statins in patients with atherosclerotic ischemic stroke in China. Chin Med J (Engl). 2012;125(10):1703–1707.
26.
ZhangDGeLLiJ. Current statin use for patients with atherosclerotic cardiovascular disease in 39 large Chinese hospitals. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(5):397–401.
27.
Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
